US Stock MarketDetailed Quotes

PSTX Poseida Therapeutics

Watchlist
  • 2.370
  • -0.010-0.42%
Close Oct 31 16:00 ET
  • 2.370
  • 0.0000.00%
Post 16:01 ET
230.21MMarket Cap-2008P/E (TTM)
Full Hours
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    Sep 27 15:33
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
    Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received at least one prior BCMA- and/or GPRC5D-targeting treatment modality
    Differentiated P-BCMA-ALLO1 ...
    Jaguar8
    Jaguar8
    Sep 16 07:05
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
    FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month
    RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant u...
    2
    Jaguar8
    Jaguar8
    Sep 5 08:01
    NEWS
    $Poseida Therapeutics (PSTX.US)$
    Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
    Poseida Therapeutics (Nasdaq: PSTX) will present new clinical data from its ongoing Phase 1 study of P-BCMA-ALLO1, an investigational off-the-shelf allogeneic CAR-T cell therapy for relapsed/refractory multiple myeloma, at the 21st International Myeloma S...
    Jaguar8
    Jaguar8
    May 1 12:31
    $Poseida Therapeutics (PSTX.US)$
    NEWS
    Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
    Jaguar8
    Jaguar8
    Apr 8 11:49
    $Poseida Therapeutics (PSTX.US)$
    NEWS
    Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data